Showing results (21-30 of 325) with videos related to
Sort By:
Pageof 33
The Medical Clinics of North America|May 1, 1994
Current trends in the development of anticoagulant and antithrombotic drugsJ Fareed, D Hoppensteadt, J M Walenga, et al.Critical Reviews in Clinical Laboratory Sciences|January 1, 1986
In vitro evaluation of heparin fractions: old vs. new methodsJ M Walenga, J Fareed, D Hoppensteadt, et al.Haemostasis|January 1, 1991
Recombinant hirudin--initial observations in reconstructive microsurgeryK Narayanan, J M Walenga, M D Liang, et al.Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|June 10, 1998
Molecular markers of hemostatic activation and inflammation following major injury: effect of therapy with IFN-gammaD J Dries, J M Walenga, D Hoppensteadt, et al.Seminars in Thrombosis and Hemostasis|October 1, 1984
Performance characteristics of a simple radioimmunoassay for fibrinopeptide AJ M Walenga, D Hoppensteadt, R M Emanuele, et al.Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 22, 2000
Heparin-induced thrombocytopenia: clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitorsS Haas, J M Walenga, W P Jeske, et al.Expert Opinion on Investigational Drugs|July 5, 2005
Pharmacology of argatrobanW Jeske, J M Walenga, B E Lewis, et al.The Annals of Thoracic Surgery|March 1, 1993
Effects of aprotinin on anticoagulant monitoring: implications in cardiovascular surgeryD M Najman, J M Walenga, J Fareed, et al.Haemostasis|January 1, 1988
Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparinsJ Fareed, J M Walenga, D Hoppensteadt, et al.Seminars in Thrombosis and Hemostasis|April 1, 1991
Comparative studies on various assays for the laboratory evaluation of r-hirudinJ M Walenga, D Hoppensteadt, M Koza, et al.Pageof 33